Free Trial
→ Man who predicted $100K Bitcoin sees a huge run coming for another coin … (From Weiss Ratings) (Ad) Buy AKRO Stock  Free AKRO Stock Alerts

Akero Therapeutics (AKRO) Financials

Akero Therapeutics logo
$46.00 -0.36 (-0.78%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$47.35 +1.35 (+2.93%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Akero Therapeutics

Annual Income Statements for Akero Therapeutics

This table shows Akero Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -251 -152 -112 -101 -79 -44
Consolidated Net Income / (Loss)		 -252 -152 -112 -101 -79 -44
Net Income / (Loss) Continuing Operations		 -252 -152 -112 -101 -79 -44
Total Pre-Tax Income 		-252 -152 -112 -101 -79 -44
Total Operating Income		 -285 -173 -115 -101 -80 -46
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 285 173 115 101 80 46
Selling, General & Admin Expense		 38 31 30 19 15 8.61
Research & Development Expense		 247 142 85 82 65 37
Total Other Income / (Expense), net		 33 21 3.12 0.11 0.95 1.90
Interest Expense		 4.67 3.10 0.74 0.00 - -
Interest & Investment Income		 38 24 3.86 0.11 - -
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.68 -0.23 -0.06 0.02 -0.00 0.01
Basic Earnings per Share		 ($3.75) ($2.89) ($2.87) ($2.89) ($2.52) ($2.90)
Weighted Average Basic Shares Outstanding		 67.14M 52.57M 38.98M 34.83M 31.46M 15.07M
Diluted Earnings per Share		 ($3.75) ($2.89) ($2.87) ($2.89) ($2.52) ($2.90)
Weighted Average Diluted Shares Outstanding		 67.14M 52.57M 38.98M 34.83M 31.46M 15.07M
Weighted Average Basic & Diluted Shares Outstanding		 79.62M 56.30M 46.97M 34.83M 31.46M 15.07M
Cash Dividends to Common per Share		 $0.00 $0.00 - $0.00 $0.00 $0.00

Quarterly Income Statements for Akero Therapeutics

This table shows Akero Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -71 -70 -56 -54 -54 -40 -31 -26 -23 -36
Consolidated Net Income / (Loss)		 -70 -73 -56 -53 -55 -40 -31 -26 -23 -36
Net Income / (Loss) Continuing Operations		 -70 -73 -56 -53 -55 -40 -31 -26 -23 -36
Total Pre-Tax Income 		-70 -73 -56 -53 -55 -40 -31 -26 -22 -36
Total Operating Income		 -78 -82 -66 -60 -62 -47 -36 -29 -25 -36
Total Operating Expenses		 78 82 66 60 62 47 36 29 25 36
Selling, General & Admin Expense		 8.73 9.47 10 9.30 8.48 7.98 7.64 6.97 7.10 11
Research & Development Expense		 69 72 55 51 53 39 28 22 18 25
Total Other Income / (Expense), net		 8.00 9.00 9.75 6.61 6.69 6.96 4.55 2.92 3.50 -0.32
Interest Expense		 1.20 1.25 1.23 0.99 0.90 0.89 0.86 0.46 0.36 0.32
Interest & Investment Income		 9.20 10 11 7.60 7.58 7.84 5.40 3.38 - -
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 1.16 -2.36 0.18 0.35 -0.78 0.26 0.27 0.02 -0.04 -0.00
Basic Earnings per Share		 ($0.99) ($1.05) ($0.81) ($0.90) ($1.03) ($0.71) ($0.60) ($0.55) ($0.44) ($0.92)
Weighted Average Basic Shares Outstanding		 67.14M 69.44M 69.16M 59.31M 52.57M 55.61M 51.87M 46.94M 38.98M 38.66M
Diluted Earnings per Share		 ($0.99) ($1.05) ($0.81) ($0.90) ($1.03) ($0.71) ($0.60) ($0.55) ($0.44) ($0.92)
Weighted Average Diluted Shares Outstanding		 67.14M 69.44M 69.16M 59.31M 52.57M 55.61M 51.87M 46.94M 38.98M 38.66M
Weighted Average Basic & Diluted Shares Outstanding		 79.62M 69.80M 69.43M 69.15M 56.30M 55.71M 55.60M 50.09M 46.97M 46.76M

Annual Cash Flow Statements for Akero Therapeutics

This table details how cash moves in and out of Akero Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 106 -16 99 -37 123 -11
Net Cash From Operating Activities		 -230 -145 -93 -80 -71 -36
Net Cash From Continuing Operating Activities		 -230 -145 -93 -80 -71 -36
Net Income / (Loss) Continuing Operations		 -252 -152 -112 -101 -79 -44
Consolidated Net Income / (Loss)		 -252 -152 -112 -101 -79 -44
Depreciation Expense		 0.02 0.03 0.04 0.04 0.02 0.00
Amortization Expense		 -13 -9.11 0.19 1.07 0.08 -0.10
Non-Cash Adjustments To Reconcile Net Income		 31 22 24 10 6.08 1.77
Changes in Operating Assets and Liabilities, net		 3.00 -6.33 -4.46 9.73 2.22 6.46
Net Cash From Investing Activities		 -110 -224 -64 42 -9.76 -72
Net Cash From Continuing Investing Activities		 -110 -224 -64 42 -9.76 -72
Acquisitions		 -1.00 0.00 0.00 - - -
Purchase of Investments		 -516 -433 -101 -44 -115 -72
Sale and/or Maturity of Investments		 407 210 38 86 105 0.00
Net Cash From Financing Activities		 446 353 256 0.60 203 96
Net Cash From Continuing Financing Activities		 446 353 256 0.60 203 96
Repayment of Debt		 0.00 0.00 0.00 0.00 - -
Repurchase of Preferred Equity		 0.00 0.00 0.00 0.00 - -
Repurchase of Common Equity		 -0.84 -0.78 -0.86 -0.52 0.00 0.00
Issuance of Debt		 10 15 10 0.00 - -
Issuance of Common Equity		 424 336 241 0.37 203 96
Other Financing Activities, net		 13 3.27 5.02 0.75 0.36 0.45
Cash Interest Paid		 3.98 2.48 0.44 0.00 - -

Quarterly Cash Flow Statements for Akero Therapeutics

This table details how cash moves in and out of Akero Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 24 5.71 -313 390 -35 -175 186 8.11 -124 196
Net Cash From Operating Activities		 -67 -70 -57 -35 -49 -50 -22 -25 -26 -25
Net Cash From Continuing Operating Activities		 -67 -70 -57 -35 -49 -49 -22 -25 -25 -25
Net Income / (Loss) Continuing Operations		 -70 -73 -56 -53 -55 -40 -31 -26 -23 -36
Consolidated Net Income / (Loss)		 -70 -73 -56 -53 -55 -40 -31 -26 -23 -36
Depreciation Expense		 0.02 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 -2.84 -3.57 -3.29 -2.81 -3.53 -3.15 -1.26 -1.17 -0.10 0.10
Non-Cash Adjustments To Reconcile Net Income		 7.34 7.47 8.71 7.94 5.61 6.06 5.07 5.06 4.39 12
Changes in Operating Assets and Liabilities, net		 -1.58 -1.61 -6.88 13 3.93 -13 5.16 -2.71 -6.72 -1.02
Net Cash From Investing Activities		 15 73 -256 58 13 -126 -128 18 -101 3.00
Net Cash From Continuing Investing Activities		 15 73 -256 58 13 -126 -128 18 -101 3.00
Purchase of Investments		 -80 -58 -339 -39 -58 -161 -189 -25 -101 -
Sale and/or Maturity of Investments		 95 131 85 97 71 36 61 43 0.00 3.00
Net Cash From Financing Activities		 76 3.07 -0.15 367 0.50 0.81 337 15 2.72 218
Net Cash From Continuing Financing Activities		 76 3.07 -0.15 367 0.50 0.81 337 15 2.72 218
Repurchase of Common Equity		 -0.03 -0.06 -0.48 -0.27 -0.03 - -0.44 -0.30 -0.17 -0.38
Issuance of Common Equity		 68 - 0.32 355 0.08 - 336 0.00 0.10 216
Other Financing Activities, net		 8.24 3.13 0.00 1.77 0.45 0.81 1.56 0.46 2.79 2.08
Cash Interest Paid		 1.03 1.09 1.09 0.77 0.77 0.77 0.67 0.28 0.25 0.19

Annual Balance Sheets for Akero Therapeutics

This table presents Akero Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2018
Total Assets		 826 580 357 196 273 138 77 77
Total Current Assets		 770 560 355 194 271 138 77 77
Cash & Equivalents		 340 234 250 150 187 65 76 76
Short-Term Investments		 403 316 102 38 81 72 - -
Prepaid Expenses		 27 9.95 3.72 5.32 2.96 1.65 1.16 1.16
Plant, Property, & Equipment, net		 0.00 0.02 0.05 0.09 0.13 0.00 0.00 0.00
Total Noncurrent Assets		 56 20 1.35 1.88 1.86 0.07 0.02 0.02
Long-Term Investments		 55 19 0.00 - - - - -
Other Noncurrent Operating Assets		 0.76 1.01 1.35 1.88 1.86 0.07 0.02 0.02
Total Liabilities & Shareholders' Equity		 826 580 357 196 273 138 77 77
Total Liabilities		 76 45 30 26 15 9.39 2.34 2.34
Total Current Liabilities		 40 19 19 25 13 9.37 2.34 2.34
Accounts Payable		 9.03 7.04 7.97 6.71 3.43 0.95 1.37 1.37
Accrued Expenses		 31 12 11 18 9.68 8.42 0.97 0.97
Total Noncurrent Liabilities		 36 26 11 1.31 1.52 0.02 0.00 0.00
Long-Term Debt		 35 25 9.54 0.00 - - - -
Other Noncurrent Operating Liabilities		 0.72 0.87 1.38 1.31 1.52 0.02 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 750 535 327 169 259 129 -50 -50
Total Preferred & Common Equity		 750 535 327 169 259 129 -50 -50
Total Common Equity		 750 535 327 169 259 129 -50 -50
Common Stock		 1,575 1,109 749 479 468 259 37 37
Retained Earnings		 -826 -574 -422 -310 -210 -130 -87 -87
Accumulated Other Comprehensive Income / (Loss)		 0.95 0.27 0.04 -0.03 -0.00 -0.01 - -

Quarterly Balance Sheets for Akero Therapeutics

This table presents Akero Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 818 865 912 635 664 349 379
Total Current Assets		 747 776 911 576 643 347 378
Cash & Equivalents		 316 310 624 270 444 258 374
Short-Term Investments		 401 450 280 285 195 85 0.00
Prepaid Expenses		 30 16 7.62 21 3.76 4.27 3.94
Plant, Property, & Equipment, net		 0.02 0.02 0.02 0.02 0.03 0.04 0.06
Total Noncurrent Assets		 71 89 0.95 59 21 1.29 1.41
Long-Term Investments		 70 88 0.00 58 19 - -
Other Noncurrent Operating Assets		 0.82 0.88 0.95 1.07 1.13 1.29 1.41
Total Liabilities & Shareholders' Equity		 818 865 912 635 664 349 379
Total Liabilities		 79 67 66 52 47 42 36
Total Current Liabilities		 43 31 30 28 22 17 25
Accounts Payable		 25 15 14 11 10 7.08 6.01
Accrued Expenses		 18 17 16 15 11 9.60 19
Total Noncurrent Liabilities		 36 36 36 24 26 26 11
Long-Term Debt		 35 35 35 23 25 25 9.45
Other Noncurrent Operating Liabilities		 0.81 0.84 0.93 0.98 1.04 1.18 1.21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 738 798 846 583 616 306 344
Total Preferred & Common Equity		 738 798 846 583 616 306 344
Total Common Equity		 738 798 846 583 616 306 344
Common Stock		 1,492 1,482 1,474 1,103 1,096 754 743
Retained Earnings		 -756 -683 -627 -519 -479 -448 -399
Accumulated Other Comprehensive Income / (Loss)		 2.10 -0.26 -0.08 -0.51 -0.25 0.02 0.00

Annual Metrics And Ratios for Akero Therapeutics

This table displays calculated financial ratios and metrics derived from Akero Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -63.74% -58.32% -15.18% -26.13% -80.37% 0.00%
EBIT Growth		 -65.11% -50.12% -14.14% -27.37% -81.02% 0.00%
NOPAT Growth		 -65.11% -50.12% -14.14% -25.87% -75.58% 0.00%
Net Income Growth		 -66.09% -35.46% -11.17% -27.23% -81.02% 0.00%
EPS Growth		 -29.76% -0.70% 0.69% -14.68% 13.10% 0.00%
Operating Cash Flow Growth		 -58.29% -57.12% -16.11% -12.54% -98.74% 0.00%
Free Cash Flow Firm Growth		 -54.24% -50.85% -38.05% -13.01% 0.00% 0.00%
Invested Capital Growth		 -37.65% 41.20% 19.86% -97.92% -26.08% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -5.47% -28.08% 5.40% -2.48% 0.00% 0.00%
EBIT Q/Q Growth		 -6.00% -26.72% 5.75% -2.70% 0.00% 0.00%
NOPAT Q/Q Growth		 -6.00% -26.72% 5.75% -2.70% 0.00% 0.00%
Net Income Q/Q Growth		 -6.25% -26.85% 7.71% -2.77% 0.00% 0.00%
EPS Q/Q Growth		 1.06% -25.65% 14.58% -1.05% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -8.72% -18.91% 1.27% -4.32% -19.89% 0.00%
Free Cash Flow Firm Q/Q Growth		 -9.18% -14.18% -4.31% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 8.83% -79.85% 27.09% -16.39% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 88.31% 87.79% 97.29% 99.89% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.22% -35.22% -45.20% -47.11% -40.89% -43.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -39.22% -35.22% -45.20% -47.11% -40.89% -16.65%
Return on Equity Simple (ROE_SIMPLE)		 -33.60% -28.35% -34.31% -59.59% -30.62% -33.99%
Net Operating Profit after Tax (NOPAT)		 -200 -121 -81 -71 -56 -32
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.00% -6.94% -11.85% -13.21% -11.41% -8.65%
Return On Investment Capital (ROIC_SIMPLE)		 -25.44% -21.60% -23.98% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -285 -173 -115 -101 -79 -44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -298 -182 -115 -100 -79 -44
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 2.59 2.43 7.85 4.36 3.46 4.92
Price to Tangible Book Value (P/TBV)		 2.59 2.43 7.85 4.36 3.46 4.92
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.05 0.05 0.03 0.00 0.00 0.00
Long-Term Debt to Equity		 0.05 0.05 0.03 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.07 -1.07 -1.04 -1.06
Leverage Ratio		 1.09 1.09 1.11 1.10 1.06 1.06
Compound Leverage Factor		 0.97 0.95 1.08 1.09 1.06 1.06
Debt to Total Capital		 4.49% 4.46% 2.84% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.49% 4.46% 2.84% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.51% 95.54% 97.16% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.12 -0.14 -0.08 0.00 0.00 0.00
Net Debt to EBITDA		 2.56 2.99 2.98 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.12 -0.14 -0.08 0.00 0.00 0.00
Debt to NOPAT		 -0.18 -0.21 -0.12 0.00 0.00 0.00
Net Debt to NOPAT		 3.82 4.50 4.24 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.18 -0.21 -0.12 0.00 0.00 0.00
Altman Z-Score		 13.90 16.11 49.65 13.86 35.85 39.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 61.28%
Liquidity Ratios		 - - - - - -
Current Ratio		 19.38 29.27 18.61 7.70 20.70 14.73
Quick Ratio		 18.69 28.75 18.42 7.49 20.47 14.56
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -196 -127 -84 -61 -54 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -47,840.54% 0.00%
Free Cash Flow to Firm to Interest Expense		 -42.07 -41.09 -114.22 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -49.29 -46.91 -125.19 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -49.29 -46.91 -125.19 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -12 -9.02 -15 -19 -9.68 -7.67
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.40 6.32 3.80 -9.47 -2.00 0.00
Enterprise Value (EV)		 1,179 756 2,221 550 627 497
Market Capitalization		 1,942 1,301 2,563 738 896 634
Book Value per Share		 $10.75 $9.61 $6.98 $4.85 $7.45 $4.51
Tangible Book Value per Share		 $10.75 $9.61 $6.98 $4.85 $7.45 $4.51
Total Capital		 785 560 336 169 259 129
Total Debt		 35 25 9.54 0.00 0.00 0.00
Total Long-Term Debt		 35 25 9.54 0.00 0.00 0.00
Net Debt		 -763 -544 -342 -188 -268 -136
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.15 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -9.18 -15 -20 -10 -7.72
Debt-free Net Working Capital (DFNWC)		 731 541 336 168 258 129
Net Working Capital (NWC)		 731 541 336 168 258 129
Net Nonoperating Expense (NNE)		 52 31 31 30 23 12
Net Nonoperating Obligations (NNO)		 -763 -544 -342 -188 -268 -136
Total Depreciation and Amortization (D&A)		 -12 -9.08 0.24 1.11 0.10 -0.10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($3.75) ($2.89) ($2.87) ($2.89) ($2.52) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 67.14M 52.57M 38.98M 35.01M 34.77M 0.00
Adjusted Diluted Earnings per Share		 ($3.75) ($2.89) ($2.87) ($2.89) ($2.52) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 67.14M 52.57M 38.98M 34.83M 34.77M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.89) ($2.52) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 79.62M 56.30M 46.97M 34.83M 31.46M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -200 -121 -81 -71 -56 -32
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -61.14 -55.78 -155.83 0.00 0.00 0.00
NOPAT to Interest Expense		 -42.80 -39.05 -109.08 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -61.14 -55.78 -155.83 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -42.80 -39.05 -109.08 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.33% -0.51% -0.77% -0.52% 0.00% 0.00%

Quarterly Metrics And Ratios for Akero Therapeutics

This table displays calculated financial ratios and metrics derived from Akero Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -23.63% -71.36% -87.19% -109.84% -156.36% -38.29% -34.00% -15.46% 20.45% -50.30%
EBIT Growth		 -26.11% -75.27% -84.52% -108.51% -143.40% -29.16% -29.12% -10.37% 21.64% -48.20%
NOPAT Growth		 -26.11% -75.27% -84.52% -108.51% -143.40% -29.16% -29.12% -10.37% 21.64% -48.20%
Net Income Growth		 -26.89% -83.33% -80.12% -106.51% -139.33% -11.58% -13.43% 0.76% 28.88% -46.08%
EPS Growth		 3.88% -47.89% -35.00% -63.64% -134.09% 22.83% 22.08% 25.68% 52.69% -31.43%
Operating Cash Flow Growth		 -37.97% -41.64% -156.61% -42.66% -90.63% -101.91% -14.76% -7.68% 4.45% -68.59%
Free Cash Flow Firm Growth		 -3.20% 0.15% -60.66% -18.39% -129.82% -135.44% -381.36% -695.16% -63.20% -244.13%
Invested Capital Growth		 -37.65% -171.54% 13.70% -84.40% 41.20% 76.16% 22.73% 34.92% 19.86% -27.93%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 5.19% -23.53% -9.99% 4.03% -31.42% -34.94% -23.29% -17.25% 29.11% -30.75%
EBIT Q/Q Growth		 4.50% -24.28% -9.65% 3.10% -32.73% -30.83% -23.91% -13.11% 29.57% -30.79%
NOPAT Q/Q Growth		 4.50% -24.28% -9.65% 3.10% -32.73% -30.83% -23.91% -13.11% 29.57% -30.79%
Net Income Q/Q Growth		 3.69% -29.86% -4.95% 3.34% -39.15% -27.59% -20.33% -12.02% 35.12% -29.70%
EPS Q/Q Growth		 5.71% -29.63% 10.00% 12.62% -45.07% -18.33% -9.09% -25.00% 52.17% -19.48%
Operating Cash Flow Q/Q Growth		 4.73% -22.58% -63.50% 27.74% 2.20% -122.07% 9.11% 3.43% -3.59% -26.22%
Free Cash Flow Firm Q/Q Growth		 -5.42% -0.29% -53.22% 36.29% -2.00% -61.36% -12.91% -23.66% -4.49% -229.92%
Invested Capital Q/Q Growth		 8.83% 10.97% 32.32% -150.57% -79.85% 71.70% -44.60% 20.10% 27.09% 8.27%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 105.20% 97.60%
Interest Burden Percent		 89.75% 88.99% 85.16% 88.97% 89.19% 85.08% 87.24% 89.84% 86.23% 100.90%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.22% -35.90% -28.87% -31.11% -35.22% -25.82% -30.21% -49.39% -45.20% -44.79%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -39.22% -35.90% -28.87% -31.11% -35.22% -25.82% -30.21% -49.39% -45.20% -44.79%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -32.13% -25.58% -21.18% 0.00% -20.52% -18.74% -36.51% 0.00% -35.34%
Net Operating Profit after Tax (NOPAT)		 -55 -57 -46 -42 -43 -33 -25 -20 -18 -25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.36% -2.32% -1.38% -1.92% -2.68% -1.48% -1.53% -2.36% -1.99% -3.55%
Return On Investment Capital (ROIC_SIMPLE)		 -6.95% - - - -7.73% - - - -5.29% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -78 -82 -66 -60 -62 -47 -36 -29 -25 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -81 -85 -69 -63 -65 -50 -37 -30 -26 -36
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.59 2.70 2.03 1.68 2.43 4.82 3.79 5.87 7.85 3.72
Price to Tangible Book Value (P/TBV)		 2.59 2.70 2.03 1.68 2.43 4.82 3.79 5.87 7.85 3.72
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.05 0.05 0.04 0.04 0.05 0.04 0.04 0.08 0.03 0.03
Long-Term Debt to Equity		 0.05 0.05 0.04 0.04 0.05 0.04 0.04 0.08 0.03 0.03
Financial Leverage		 -1.02 -1.01 -1.02 -1.03 -1.03 -1.03 -1.05 -1.07 -1.07 -1.07
Leverage Ratio		 1.09 1.10 1.08 1.09 1.09 1.10 1.11 1.15 1.11 1.11
Compound Leverage Factor		 0.98 0.98 0.92 0.97 0.97 0.93 0.97 1.03 0.96 1.12
Debt to Total Capital		 4.49% 4.54% 4.20% 3.95% 4.46% 4.09% 3.86% 7.44% 2.84% 2.68%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.34% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.49% 4.54% 4.20% 3.95% 4.46% 3.74% 3.86% 7.44% 2.84% 2.68%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.51% 95.46% 95.80% 96.05% 95.54% 95.91% 96.14% 92.56% 97.16% 97.32%
Debt to EBITDA		 -0.12 -0.12 -0.14 -0.16 -0.14 -0.17 -0.19 -0.21 -0.08 -0.08
Net Debt to EBITDA		 2.56 2.66 3.29 4.05 2.99 4.14 4.94 2.68 2.98 3.00
Long-Term Debt to EBITDA		 -0.12 -0.12 -0.14 -0.16 -0.14 -0.16 -0.19 -0.21 -0.08 -0.08
Debt to NOPAT		 -0.18 -0.19 -0.21 -0.24 -0.21 -0.26 -0.28 -0.30 -0.12 -0.11
Net Debt to NOPAT		 3.82 3.99 4.96 6.08 4.50 6.16 7.20 3.86 4.24 4.26
Long-Term Debt to NOPAT		 -0.18 -0.19 -0.21 -0.24 -0.21 -0.24 -0.28 -0.30 -0.12 -0.11
Altman Z-Score		 14.73 14.49 14.21 12.91 16.74 31.98 29.56 24.45 50.48 20.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 19.38 17.25 24.89 30.12 29.27 20.25 29.78 20.84 18.61 14.97
Quick Ratio		 18.69 16.57 24.39 29.86 28.75 19.50 29.60 20.58 18.42 14.82
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -51 -49 -48 -32 -50 -49 -30 -27 -22 -21
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -42.68 -38.99 -39.36 -31.91 -55.33 -54.80 -35.19 -58.44 -59.66 -63.79
Operating Cash Flow to Interest Expense		 -55.91 -56.52 -46.67 -35.46 -54.21 -55.99 -26.12 -53.90 -70.46 -76.00
Operating Cash Flow Less CapEx to Interest Expense		 -55.91 -56.52 -46.67 -35.46 -54.21 -55.99 -26.12 -53.90 -70.46 -76.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -12 -14 -15 -23 -9.02 -5.02 -18 -12 -15 -21
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.40 -8.61 2.43 -10 6.32 16 5.22 6.58 3.80 -4.60
Enterprise Value (EV)		 1,179 1,240 809 553 756 2,224 1,704 1,479 2,221 915
Market Capitalization		 1,942 1,992 1,622 1,422 1,301 2,812 2,339 1,797 2,563 1,279
Book Value per Share		 $10.75 $10.63 $11.54 $15.03 $9.61 $10.49 $12.31 $6.52 $6.98 $9.14
Tangible Book Value per Share		 $10.75 $10.63 $11.54 $15.03 $9.61 $10.49 $12.31 $6.52 $6.98 $9.14
Total Capital		 785 773 833 881 560 608 641 331 336 353
Total Debt		 35 35 35 35 25 25 25 25 9.54 9.45
Total Long-Term Debt		 35 35 35 35 25 23 25 25 9.54 9.45
Net Debt		 -763 -752 -813 -869 -544 -588 -634 -319 -342 -365
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -14 -15 -23 -9.18 -5.12 -18 -12 -15 -21
Debt-free Net Working Capital (DFNWC)		 731 704 745 881 541 550 622 331 336 353
Net Working Capital (NWC)		 731 704 745 881 541 548 622 331 336 353
Net Nonoperating Expense (NNE)		 15 16 9.97 11 12 7.03 6.14 5.70 5.27 10
Net Nonoperating Obligations (NNO)		 -763 -752 -813 -869 -544 -588 -634 -319 -342 -365
Total Depreciation and Amortization (D&A)		 -2.82 -3.57 -3.29 -2.81 -3.52 -3.15 -1.25 -1.16 -0.09 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.99) ($1.05) ($0.81) ($0.90) ($1.03) ($0.71) ($0.60) ($0.55) ($0.44) ($0.92)
Adjusted Weighted Average Basic Shares Outstanding		 67.14M 69.44M 69.16M 59.31M 52.57M 55.61M 51.87M 46.94M 38.98M 38.66M
Adjusted Diluted Earnings per Share		 ($0.99) ($1.05) ($0.81) ($0.90) ($1.03) ($0.71) ($0.60) ($0.55) ($0.44) ($0.92)
Adjusted Weighted Average Diluted Shares Outstanding		 67.14M 69.44M 69.16M 59.31M 52.57M 55.61M 51.87M 46.94M 38.98M 38.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 79.62M 69.80M 69.43M 69.15M 56.30M 55.71M 55.60M 50.09M 46.97M 46.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -55 -57 -46 -42 -43 -33 -25 -20 -18 -25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -65.02 -65.57 -53.40 -60.50 -68.98 -52.49 -41.57 -62.92 -70.22 -111.39
NOPAT to Interest Expense		 -45.51 -45.90 -37.38 -42.35 -48.28 -36.75 -29.10 -44.04 -49.15 -77.97
EBIT Less CapEx to Interest Expense		 -65.02 -65.57 -53.40 -60.50 -68.98 -52.49 -41.57 -62.92 -70.22 -111.39
NOPAT Less CapEx to Interest Expense		 -45.51 -45.90 -37.38 -42.35 -48.28 -36.75 -29.10 -44.04 -49.15 -77.97
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.33% -0.36% -0.38% -0.42% -0.51% -0.76% -1.12% -1.03% -0.77% -0.60%

Frequently Asked Questions About Akero Therapeutics' Financials

When does Akero Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Akero Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Akero Therapeutics' net income changed over the last 5 years?

Akero Therapeutics' net income appears to be on an upward trend, with a most recent value of -$252.06 million in 2024, rising from -$43.76 million in 2019. The previous period was -$151.76 million in 2023. See Akero Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Akero Therapeutics's operating income?
Akero Therapeutics's total operating income in 2024 was -$285.42 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $285.42 million
How has Akero Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Akero Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Akero Therapeutics have?

Akero Therapeutics' total liabilities were at $75.77 million at the end of 2024, a 68.5% increase from 2023, and a 3,135.4% increase since 2017.

How much cash does Akero Therapeutics have?

In the past 7 years, Akero Therapeutics' cash and equivalents has ranged from $64.79 million in 2019 to $340.24 million in 2024, and is currently $340.24 million as of their latest financial filing in 2024.

How has Akero Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Akero Therapeutics' book value per share changed from 4.51 in 2019 to 10.75 in 2024, a change of 138.4%.


Related Companies

This page (NASDAQ:AKRO) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored